SepMate™-15 (IVD) Tubes for Density Gradient Centrifugation

总览

将SepMate™离心管整合到密度梯度离心步骤中，能够简化外周血单个核细胞(PBMC)分离流程。

SepMate™离心管配有插件，可在密度梯度介质与血液之间形成屏障，既省去精细分层操作，又能通过简单倾倒轻松获取单个核细胞。本产品可与RosetteSep™联用分离特定免疫细胞亚群。

SepMate™按照cGMP标准生产，并在澳大利亚、加拿大、欧洲和美国注册为体外诊断(IVD)设备。在中国，该产品被中国食品药品监督管理局（CFDA）认定为非医疗器械，因此可被用于一般实验室耗材。终端用户需自行评估该产品是否适用于其特定用途。其它国家的用户，可参考SepMate™-15（RUO）（产品号 #86415）和SepMate™-50（RUO）（产品号 #86450）。

查阅SepMate™常见问题解答(FAQs)。

SepMate™离心管配有插件，可在密度梯度介质与血液之间形成屏障，既省去精细分层操作，又能通过简单倾倒轻松获取单个核细胞。本产品可与RosetteSep™联用分离特定免疫细胞亚群。

SepMate™按照cGMP标准生产，并在澳大利亚、加拿大、欧洲和美国注册为体外诊断(IVD)设备。在中国，该产品被中国食品药品监督管理局（CFDA）认定为非医疗器械，因此可被用于一般实验室耗材。终端用户需自行评估该产品是否适用于其特定用途。其它国家的用户，可参考SepMate™-15（RUO）（产品号 #86415）和SepMate™-50（RUO）（产品号 #86450）。

查阅SepMate™常见问题解答(FAQs)。

SepMate™离心管配有插件，可在密度梯度介质与血液之间形成屏障，既省去精细分层操作，又能通过简单倾倒轻松获取单个核细胞。本产品可与RosetteSep™联用分离特定免疫细胞亚群。

SepMate™按照cGMP标准生产，并在澳大利亚、加拿大、欧洲和美国注册为体外诊断(IVD)设备。在中国，该产品被中国食品药品监督管理局（CFDA）认定为非医疗器械，因此可被用于一般实验室耗材。终端用户需自行评估该产品是否适用于其特定用途。其它国家的用户，可参考SepMate™-15（RUO）（产品号 #86415）和SepMate™-50（RUO）（产品号 #86450）。

查阅SepMate™常见问题解答(FAQs)。

SepMate™离心管配有插件，可在密度梯度介质与血液之间形成屏障，既省去精细分层操作，又能通过简单倾倒轻松获取单个核细胞。本产品可与RosetteSep™联用分离特定免疫细胞亚群。

SepMate™按照cGMP标准生产，并在澳大利亚、加拿大、欧洲和美国注册为体外诊断(IVD)设备。在中国，该产品被中国食品药品监督管理局（CFDA）认定为非医疗器械，因此可被用于一般实验室耗材。终端用户需自行评估该产品是否适用于其特定用途。其它国家的用户，可参考SepMate™-15（RUO）（产品号 #86415）和SepMate™-50（RUO）（产品号 #86450）。

查阅SepMate™常见问题解答(FAQs)。

包含
Polypropylene tube containing an insert

亚型
离心管

细胞类型
B 细胞，树突状细胞（DCs），单核细胞，单个核细胞，NK 细胞，T 细胞，T 细胞，CD4+，T 细胞，CD8+，T 细胞，其他亚群，T 细胞，调节性细胞

种属
人

样本来源
Bone Marrow，Whole Blood

筛选方法
Negative

应用
细胞分选，体外诊断

品牌
SepMate

研究领域
嵌合体，HLA，免疫

查看更多显示更少

实验数据

PBMC recovery from fresh whole blood using SepMate™-50 versus standard density gradient centrifugation. Graph also shows PBMC recovery from a 48 hour-old sample using SepMate™. n in each group = 7

Figure 1. Recovery of mononuclear cells (MNCs) from peripheral blood using SepMate™-50 versus standard density gradient centrifiguation.

Recovery of MNCs from fresh and 48-hour post blood draw enriched by density gradient centrifugation with SepMate™ (purple) or without (grey). There was no significant difference in the recovery of MNCS with and without SepMate™.

Figure 2. Human CD4+ T Cell Isolation using SepMate™-50 and RosetteSep™ Human CD4+ T Cell Enrichment Cocktail

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type

Product Name

Catalog #

Lot #

Language

Document Type

Product Information Sheet

Product Name

SepMate™-15 (IVD)

Catalog #

85415, 85420

Lot #

All

Language

MULTI

应用领域

本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。

Research Area

Workflow Stages

Workflow Stages for B Cell Research

Cell Sourcing

Cell Isolation

Cell Expansion

Cell Characterization

Workflow Stages for Dendritic Cell Research

Cell Sourcing

Cell Isolation

Cell Differentiation and Maturation

Cell Characterization

Workflow Stages for Hematopoietic Stem and Progenitor Cell Research

Cell Sourcing and Isolation

Expansion and Differentiation

Analysis

Workflow Stages for Total Lymphocyte Research

Cell Sourcing

Cell Isolation

Cell Characterization

Workflow Stages for Monocyte Research

Cell Sourcing

Cell Isolation

Cell Differentiation and Maturation

Cell Characterization

Workflow Stages for Natural Killer Cell Research

Cell Sourcing

Cell Isolation

Cell Expansion and Differentiation

Cell Characterization

Workflow Stages for T Cell Research

Cell Sourcing

Cell Isolation

Cell Activation, Expansion, and Differentiation

Cell Characterization

Workflow Stages for HLA Analysis

Cell Isolation

Characterization

Workflow Stages for Chimerism Analysis

Cell Isolation

Characterization

相关材料与文献

A highly potent lymphatic system-targeting nanoparticle cyclosporine prevents glomerulonephritis in mouse model of lupus. R. Ganugula et al. Science advances 2020 jun

Abstract

Cyclosporine A (CsA) is a powerful immunosuppressant, but it is an ineffective stand-alone treatment for systemic lupus erythematosus (SLE) due to poor target tissue distribution and renal toxicity. We hypothesized that CD71 (transferrin receptor 1)-directed delivery of CsA to the lymphatic system would improve SLE outcomes in a murine model. We synthesized biodegradable, ligand-conjugated nanoparticles [P2Ns-gambogic acid (GA)] targeting CD71. GA conjugation substantially increased nanoparticle association with CD3+ or CD20+ lymphocytes and with intestinal lymphoid tissues. In orally dosed MRL-lpr mice, P2Ns-GA-encapsulated CsA increased lymphatic drug delivery 4- to 18-fold over the ligand-free formulation and a commercial CsA capsule, respectively. Improved lymphatic bioavailability of CsA was paralleled by normalization of anti-double-stranded DNA immunoglobulin G titer, plasma cytokines, and glomerulonephritis. Thus, this study demonstrates the translational potential of nanoparticles that enhance the targeting of lymphatic tissues, transforming CsA into a potent single therapeutic for SLE.

View publication

A dominant autoinflammatory disease caused by non-cleavable variants of RIPK1 P. Tao et al. Nature 2020

Abstract

Activation of RIPK1 controls TNF-mediated apoptosis, necroptosis and inflammatory pathways1. Cleavage of human and mouse RIPK1 after residues D324 and D325, respectively, by caspase-8 separates the RIPK1 kinase domain from the intermediate and death domains. The D325A mutation in mouse RIPK1 leads to embryonic lethality during mouse development2,3. However, the functional importance of blocking caspase-8-mediated cleavage of RIPK1 on RIPK1 activation in humans is unknown. Here we identify two families with variants in RIPK1 (D324V and D324H) that lead to distinct symptoms of recurrent fevers and lymphadenopathy in an autosomal-dominant manner. Impaired cleavage of RIPK1 D324 variants by caspase-8 sensitized patients' peripheral blood mononuclear cells to RIPK1 activation, apoptosis and necroptosis induced by TNF. The patients showed strong RIPK1-dependent activation of inflammatory signalling pathways and overproduction of inflammatory cytokines and chemokines compared with unaffected controls. Furthermore, we show that expression of the RIPK1 mutants D325V or D325H in mouse embryonic fibroblasts confers not only increased sensitivity to RIPK1 activation-mediated apoptosis and necroptosis, but also induction of pro-inflammatory cytokines such as IL-6 and TNF. By contrast, patient-derived fibroblasts showed reduced expression of RIPK1 and downregulated production of reactive oxygen species, resulting in resistance to necroptosis and ferroptosis. Together, these data suggest that human non-cleavable RIPK1 variants promote activation of RIPK1, and lead to an autoinflammatory disease characterized by hypersensitivity to apoptosis and necroptosis and increased inflammatory response in peripheral blood mononuclear cells, as well as a compensatory mechanism to protect against several pro-death stimuli in fibroblasts.

View publication

Rheumatoid Arthritis Patients, Both Newly Diagnosed and Methotrexate Treated, Show More DNA Methylation Differences in CD4+ Memory Than in CD4+ Na\ive T Cells." K. Guderud et al. Frontiers in immunology 2020

Abstract

Background: Differences in DNA methylation have been reported in B and T lymphocyte populations, including CD4+ T cells, isolated from rheumatoid arthritis (RA) patients when compared to healthy controls. CD4+ T cells are a heterogeneous cell type with subpopulations displaying distinct DNA methylation patterns. In this study, we investigated DNA methylation using reduced representation bisulfite sequencing in two CD4+ T cell populations (CD4+ memory and na{\{i}}ve cells) in three groups: newly diagnosed disease modifying antirheumatic drugs (DMARD) na{\"{i}}ve RA patients (N = 11) methotrexate (MTX) treated RA patients (N = 18) and healthy controls (N = 9) matched for age gender and smoking status. Results: Analyses of these data revealed significantly more differentially methylated positions (DMPs) in CD4+ memory than in CD4+ na{\""{i}}ve T cells (904 vs. 19 DMPs) in RA patients compared to controls. The majority of DMPs (72{\%}) identified in newly diagnosed and DMARD na{\""{i}}ve RA patients with active disease showed increased DNA methylation (39 DMPs) whereas most DMPs (80{\%}) identified in the MTX treated RA patients in remission displayed decreased DNA methylation (694 DMPs). Interestingly we also found that about one third of the 101 known RA risk loci overlapped (±500 kb) with the DMPs. Notably introns of the UBASH3A gene harbor both the lead RA risk SNP and two DMPs in CD4+ memory T cells. Conclusion: Our results suggest that RA associated DNA methylation differences vary between the two T cell subsets but are also influenced by RA characteristics such as disease activity disease duration and/or MTX treatment."""

View publication

View All Publications

SepMate™-15 (IVD)

产品号 #（选择产品）

产品号 #85415_C

产品优势

产品组分包括

What Our Scientist Says

总览

实验数据

产品说明书及文档

应用领域

相关材料与文献

Request Pricing

更多信息

Scientists Helping Scientists™

种属	Human
Contains	Polypropylene tube containing an insert
样本来源	Bone Marrow, Whole Blood
Selection Method	Negative

SepMate™-15 (IVD)

产品号 #（选择产品）

产品号 #85415_C

产品优势

产品组分包括

What Our Scientist Says

总览

实验数据

产品说明书及文档

应用领域

相关材料与文献

技术资料 (13)

文献 (30)

Abstract

Abstract

Abstract

Request Pricing

更多信息

欢迎您关注STEMCELL Technologies的微信公众平台